0001567619-23-000460.txt : 20230105 0001567619-23-000460.hdr.sgml : 20230105 20230105162908 ACCESSION NUMBER: 0001567619-23-000460 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230103 FILED AS OF DATE: 20230105 DATE AS OF CHANGE: 20230105 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Eichorn Laura G. CENTRAL INDEX KEY: 0001861067 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40604 FILM NUMBER: 23511710 MAIL ADDRESS: STREET 1: IMAGO BIOSCIENCES, INC. STREET 2: 329 OYSTER POINT BLVD. 3RD FL CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Imago BioSciences, Inc. CENTRAL INDEX KEY: 0001623715 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 454915810 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 303 TWIN DOLPHIN DRIVE STREET 2: 6TH FLOOR CITY: REDWOOD CITY STATE: CA ZIP: 94065 BUSINESS PHONE: (415) 529-5055 MAIL ADDRESS: STREET 1: 303 TWIN DOLPHIN DRIVE STREET 2: 6TH FLOOR CITY: REDWOOD CITY STATE: CA ZIP: 94065 4 1 doc1.xml FORM 4 X0306 4 2023-01-03 0 0001623715 Imago BioSciences, Inc. IMGO 0001861067 Eichorn Laura G. C/O IMAGO BIOSCIENCES, INC. 303 TWIN DOLPHIN DRIVE, 6TH FLOOR REDWOOD CITY CA 94065 0 1 0 0 Chief Financial Officer Common Stock 2023-01-03 4 M 0 22950 2.52 A 232284 D Common Stock 2023-01-03 4 M 0 12400 4.2 A 244684 D Common Stock 2023-01-03 4 M 0 1769 22.76 A 246453 D Stock Option (Right to Buy) 2.52 2023-01-03 4 M 0 22950 0 D 2021-01-01 2027-03-28 Common Stock 22950 0 D Stock Option (Right to Buy) 4.2 2023-01-03 4 M 0 12400 0 D 2031-02-04 Common Stock 12400 11409 D Stock Option (Right to Buy) 22.76 2023-01-03 4 M 0 1769 0 D 2031-11-16 Common Stock 1769 101231 D Reflects the adjusted total which includes the purchase of 1,597 shares under the Imago Employee Stock Purchase Plan on November 30, 2022. One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from November 12, 2020 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. 25% of the shares subject to the option vest on the first anniversary measured from November 17, 2021 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. /s/ Hugh Rienhoff, as Attorney-in-fact for Laura Eichorn 2023-01-05